Literature DB >> 8852405

Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein.

H Ghiasi1, A B Nesburn, S L Wechsler.   

Abstract

Our previous studies have shown that of seven HSV-1 glycoproteins (gB, gC, gD, gE, gG, gH and gI) individually expressed in baculovirus, vaccination with gD provides the best protection against HSV-1 challenge. To establish whether vaccination with a mixture of these seven expressed glycoproteins would provide better protection against HSV-1 challenge than vaccination with gD alone, we determined the level of protection afforded by vaccination with a cocktail of the seven expressed glycoproteins. The amount of each of the seven expressed glycoproteins in the mixture was equivalent to one-seventh the amount of gD used in the gD alone vaccination. Thus, the total amount of glycoprotein was the same for the cocktail and gD alone vaccine. For neutralizing antibody titer, delayed-type hypersensitivity (DTH), and survival following lethal challenge, no difference was observed between mice vaccinated with all seven glycoproteins and those vaccinated with gD. However, for other criteria, vaccination with all seven glycoproteins appeared to provide better protection than vaccination with gD. Following ocular challenge, virus was not detected at any time in the tears of mice vaccinated with all seven glycoproteins. In contrast, virus was detected in the tears of gD vaccinated mice for up to 3 days post challenge. Mock vaccinated mice had virus in their tears for as long as 10 days. Mice vaccinated with all seven glycoproteins had no eye disease, while gD vaccinated mice had a significant amount of blepharitis. Finally, compared to gD vaccinated mice, the mice vaccinated with all seven glycoproteins were more efficiently protected against the establishment of HSV-1 latency following ocular infection. Our results therefore suggest that while for some protective criteria there was no significant difference between vaccination with gD or seven glycoproteins, vaccination with seven glycoproteins was more efficient in protecting challenged mice against some forms of eye disease, the duration of infection and the establishment of latency.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852405     DOI: 10.1016/0264-410x(95)00169-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Immunization with combined HSV-2 glycoproteins B2 : D2 gene DNAs: protection against lethal intravaginal challenges in mice.

Authors:  Hyung Hoan Lee; Soung Chul Cha; Dong June Jang; Jun Keun Lee; Dong Wan Choo; Young Sik Kim; Hong Sun Uh; Soo Young Kim
Journal:  Virus Genes       Date:  2002-10       Impact factor: 2.332

2.  The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.

Authors:  H Ghiasi; D C Roopenian; S Slanina; S Cai; A B Nesburn; S L Wechsler
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

3.  Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig.

Authors:  David I Bernstein; Julie D Earwood; Fernando J Bravo; Gary H Cohen; Roselyn J Eisenberg; Jennifer R Clark; Jeffrey Fairman; Rhonda D Cardin
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

4.  BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1.

Authors:  M Suter; A M Lew; P Grob; G J Adema; M Ackermann; K Shortman; C Fraefel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits.

Authors:  A B Nesburn; S Slanina; R L Burke; H Ghiasi; S Bahri; S L Wechsler
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccines.

Authors:  David I Bernstein; Rhonda D Cardin; Fernando J Bravo; Jane E Strasser; Nicholas Farley; Claudia Chalk; Marla Lay; Jeff Fairman
Journal:  Clin Vaccine Immunol       Date:  2009-03-11

7.  A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.

Authors:  Derek J Royer; Hem R Gurung; Jeremy K Jinkins; Joshua J Geltz; Jennifer L Wu; William P Halford; Daniel J J Carr
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

Review 8.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

9.  A role for the JAK-STAT1 pathway in blocking replication of HSV-1 in dendritic cells and macrophages.

Authors:  Kevin R Mott; David Underhill; Steven L Wechsler; Terrence Town; Homayon Ghiasi
Journal:  Virol J       Date:  2009-05-13       Impact factor: 4.099

10.  Lymphoid-related CD11c+ CD8alpha+ dendritic cells are involved in enhancing herpes simplex virus type 1 latency.

Authors:  Kevin R Mott; David Underhill; Steven L Wechsler; Homayon Ghiasi
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.